Alterations of chromosome 8, including amplification at 8q24 harboring the C-MYC oncogene, have been noted as one of the most common chromosomal abnormalities in prostate cancer (CaP) progression. However, the frequency of C-MYC alterations in CaP has remained uncertain. A recent study, using a new anti-MYC antibody, described prevalent upregulation of nuclear C-MYC protein expression as an early oncogenic alteration in CaP. Further, we have recently reported regulation of C-MYC expression by ERG and a significant correlation between C-MYC overexpression and TMPRSS2-ERG fusion in early stage CaP. These emerging data suggest that increased C-MYC expression may be a critical and early oncogenic event driving CaP progression. In this study, we assessed whether C-MYC mRNA overexpression in primary prostate tumors was predictive of more aggressive tumor or disease progression. Our approach was to quantitatively determine C-MYC mRNA expression levels in laser capture micro-dissected tumor cells and matched benign epithelial cells in a radical prostatectomy cohort with long follow-up data available. On the basis of our results, we conclude that elevated C-MYC expression in primary prostate tumor is biologically relevant and may be a predictor of future biochemical recurrence.
Introduction
Prostate cancer (CaP) is the most frequently diagnosed male cancer and it continues to be second only to lung cancer as the most frequent cause of cancer-related deaths in the United States. [1] [2] [3] The prognosis of the disease is currently assessed by serum PSA levels, pathological stage and the Gleason's grade. The function of these prognostic factors is limited because of the fact that CaP exhibits high variability in its biological behavior. Extensive efforts have been focused on further elucidation of the biological basis of CaP onset/progression that may lead to the development of new diagnostic and prognostic markers, and identification of potential therapeutic targets. [4] [5] [6] Alterations in the expression of chromosome 8 genes (losses at 8q21-22 and amplifications at 8q24) have been identified in CaP. 7 Amplification at the 8q24 locus, which includes the C-MYC proto-oncogene, has been suggested as potential prognostic factor for CaP. 8 C-MYC is a DNA-binding protein that belongs to the MYC/MAD/MAX family of basic-helix-loop-helix-zipper (bHLHz) proteins. 9 The C-MYC protein is a transcription factor that regulates a variety of cellular processes including cell growth and proliferation, cell-cycle progression, transcription, differentiation, apoptosis and cellular motility. 10 C-MYC was one of the first oncogenes identified and its overexpression at the RNA and protein levels has subsequently been linked to a wide variety of human cancers. 11 The overexpression of the C-MYC protein or the C-MYC gene has been shown in 80% of breast cancers, 70% of colon cancers, 90% of gynecological cancers, 50% of hepatocellular carcinomas and a variety of hematological tumors. It is estimated that approximately 100 000 US cancer deaths per year are associated with changes in the C-MYC gene or its expression. 12, 13 C-MYC overexpression in CaP has been a wellrecognized phenomenon since 1986, when Fleming et al. 14 showed by Northern blotting a significantly higher level of its expression in adenocarcinoma of the prostate than in BPH. However, overall frequency of C-MYC alterations has remained uncertain in CaP because of sample and reagent biases. The data from fluorescent in situ hybridization-based assays have been more consistent. It has been shown that C-MYC amplification exists both in prostatic intra-epithelial neoplasia and in primary CaP, and that the level of its amplification increases as the carcinogenesis progresses from prostatic intra-epithelial neoplasia through localized to metastatic malignancy. 4, [15] [16] [17] More recently, Sato et al.
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showed by fluorescent in situ hybridization that amplification of C-MYC is strongly associated with higher histo-pathological grades and Gleason's scores as well as with earlier disease progression and earlier cancer death. In contrast, the De Marzo laboratory recently reported that using a new anti-MYC antibody they found a prevalent and early upregulation of nuclear C-MYC protein expression in CaP. 19 Considering sensitivity and quantitative accuracy of the real-time reverse transcription polymerase chain reaction (RT-PCR) assay (TaqMan, Applied Biosystems, Foster City, CA, USA) to quantify C-MYC mRNA levels in RNA samples prepared from laser capture micro-dissected primary CaP specimens, we carefully evaluated overall frequency of C-MYC overexpression in CaP cells, prognostic features of C-MYC expression and its relationship to other previously studied gene-expression alterations (PTEN, ERG, AR, PSA/KLK3, PCA3, PMEPA1, PSGR, TMPRSS2, AMACR and LTF) in our laboratory. 20, 21 To our knowledge this is the first comprehensive and quantitative evaluation of C-MYC mRNA expression in microdissected benign and CaP specimens from patients linked to longitudinal post-treatment follow-up.
Materials and methods
Tumor specimens were obtained under an IRB-approved protocol from patients who underwent radical retropubic prostatectomy at Walter Reed Army Medical Center in Washington, DC. All tumor specimens represented hormone naive disease. Specimen processing and geneexpression analysis were performed as described. 20, 21 Briefly, benign and neoplastic prostate epithelial cells were collected by a pathologist from frozen prostatectomy specimens using laser capture micro-dissection technique. Total RNA was extracted from the dissected specimens using the MicroRNA kit (Stratagene, La Jolla, CA, USA). The RNA was quantified with RiboGreen dye (Molecular Probes, Eugene, OR, USA) and a VersaFluor fluorimeter (Bio-Rad, Herculese, CA, USA) and converted to cDNA (Sensiscript, Qiagen, Valencia, CA, USA). Altogether, 182 specimens (from 91 patients) were determined to be adequate for subsequent statistical analysis.
Quantitative gene-expression analysis was performed by TaqMan-based QRT-PCR on ABI 7700 (Applied Biosystems, Foster City, CA, USA). C-MYC probe and primers, previously reported by Latil et al., 0 . All other primers and probes have been reported. 21, 23 The TaqMan primers and probe for a-methylacyl-CoA racemase (AMACR) were 'assay on demand' (PE Applied Biosystems, Foster City, CA, USA). The expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was analyzed as endogenous control (Human GAPDH TaqMan mix, Applied Biosystems). Target gene expression in each sample was normalized to GAPDH, with negative control provided by RNA samples without reverse transcription. Standard thermal cycling conditions were 95 1C for 10 min followed by 50 cycles of 95 1C for 15 s and 60 1C for 1 min. Gene-expression results were obtained as average C T (threshold cycle) values of duplicate samples.
Expression of C-MYC in tumor tissues and in benign tissues was compared by using paired t-test analysis. The association of C-MYC expression level with standard clinical, pathological and biological characteristics was tested by using Wilcoxon's rank sum test or KruskalWallis' test. Pearson's or Spearman's correlation analyses were used to evaluate the correlation between C-MYC and other gene-expression levels (PTEN, ERG, AR, PSA/KLK3, PCA3, PMEPA1, PSGR, TMPRSS2, AMACR and LTF) in tumor tissue. 20, 21, 23 The prognostic significance of established clinical variables (race, pathologic stage and Gleason's score, margin status and PSA level at time of diagnosis) and C-MYC expression level were assessed by constructing univariate and multivariate Cox proportional hazards models. Disease progression-free survival curves across different C-MYC expression levels (categorized to quartile groups) were constructed with use of KaplanMeier survival method with log-rank test. A P-value of o0.05 (two sided) was considered indicative of statistical significance. All statistical analyses were performed by using SAS 9.1.3 (SAS Institute, Cary, NC, USA).
Immunohistochemistry experiments were performed on whole mounted prostate sections using C-MYC antibody (rabbit monoclonal, cat# 1472-1, Epitomics, Burlingame, CA, USA) as described by De Marzo and coworkers. (Table 1) .
Relationship between C-MYC and other gene levels in tumor tissue C-MYC mRNA levels were compared with that of 10 other genes (PTEN, ERG, AR, PSA/KLK3, PCA3, PMEPA1, PSGR, TMPRSS2, AMACR and LTF) previously determined in our laboratory using the same laser capture micro-dissection RNA specimens. On the basis of Pearson's correlation analysis, C-MYC expression levels were found to be positively correlated with only ERG (R ¼ 0.42, P ¼ 0.0042). There was a weak negative correlation with PCA3 (R ¼ À0.26, P ¼ 0.0160) expression. The results are summarized in Table 2 .
Correlation between C-MYC mRNA and PSA recurrence
The association of different C-MYC mRNA expression level in tumor tissue with the clinical progression-free survival was examined by the Kaplan-Meier survival analysis and log-rank test. Patients with highest C-MYC expression level (quartile 4: 2.62-fold C-MYC over GAPDH and above) exhibited a trend towards higher chance and faster speed to develop PSA recurrence than patients in the lower C-MYC quartiles (quartile 1-3: 0.008-2.62-fold C-MYC over GAPDH) (Figure 1 ; P ¼ 0.0752). On the basis of multivariate Cox proportional hazards model, C-MYC expression level in tumor tissue was found to be an independent predictor of biochemical recurrence (odds ratio ¼ 1.229, P ¼ 0.0085; Table 3 ).
C-MYC expression in different tumor foci of the same patient
The C-MYC mRNA expression described above was determined in micro-dissected cells from the index tumor (largest tumor) of each patient analyzed. Other tumor foci may have different levels of C-MYC expres- Figure 1 Kaplan-Meier PSA recurrence-free survival curves across C-MYC quartile groups (C-MYC expression in tumor tissue). Relative C-MYC-expression levels (C-MYC over GAPDH ratio) in prostate tumor cells of the patients were stratified into quartiles as follow: quartile 1: 0.008-0.38 ratio; quartile 2: 0.38-1.14 ratio; quartile 3: 1.14-2.62 ratio; quartile 4: 2.62-1550 ratio. Kaplan-Meier analysis of these four groups of patients with increasing C-MYC expression from quartile 1 to 4 is depicted in the graph.
C-MYC
To address this question, C-MYC expression was determined in a small cohort of patients (N ¼ 17) with multiple tumor foci by immunohistochemistry, using whole mounted prostate sections of radical prostatectomy specimens and the C-MYC antibody and procedure described by De Marzo and coworkers. 19 Interestingly, C-MYC expression appeared to be fairly similar in the different tumor foci of the same patients (Supplementary Table 1 ). Eight patients had the same and eight patients had similar expression of C-MYC in different tumor foci of the same patient. In one patient, the index tumor had weak C-MYC expression, but two smaller foci showed strong C-MYC expression.
Correlation between C-MYC mRNA and C-MYC protein expression C-MYC protein expression was determined in a small cohort of patients in the same tumor (index tumor) in which the C-MYC mRNA was measured from microdissected tumor cells. In eight patients with high (DCt oÀ2.0) and eight patients with low (DCt42.0) C-MYC mRNA expression in their tumor cells, C-MYC protein expression was determined by immunohistochemistry as described. 19 No strong correlation between the C-MYC mRNA and protein expression levels was apparent from this analysis (Supplementary Table 2 ). Although seven of eight patients with high C-MYC mRNA expression had strong C-MYC protein signal, four of eight patients with low C-MYC mRNA had also strong C-MYC protein signal.
Discussion
This study highlights that higher levels of C-MYC mRNA in primary prostate tumors, as determined by quantitative RT-PCR using carefully sampled micro-dissected specimens, is predictive of biochemical recurrence after radical retropubic prostatectomy.
It has been recognized that a region on chromosome 8q24, including the C-MYC locus, is frequently amplified in advanced stages of CaP, but is a rare event in primary prostate tumors. 16 The determination of C-MYC expression in CaP was hampered by the lack of specific antibodies and by the heterogeneity of prostate tissue. A recent report, using a new anti-MYC antibody, found the upregulation of nuclear C-MYC protein expression a highly prevalent and early change in CaP. 19 These results suggest that increased C-MYC expression may be a critical and early oncogenic event driving CaP progression. As C-MYC protein expression did not correlate with 8q24 amplification, an alternative mechanism must be responsible for the C-MYC overexpression. 7, 19 Our laboratory has recently reported that TMPRSS2-ERG fusion, a common genomic alteration in CaP, activates C-MYC and abrogates prostate epithelial differentiation, suggesting a potential mechanism for the early C-MYC overexpression in a significant subset of CaP. 24 Indeed, in a cohort of well/moderately differentiated prostate tumors, in which other confounding genomic alterations may be minimal, we did find a highly significant correlation of ERG and C-MYC expression. 24 In this study, we further assessed whether C-MYC mRNA overexpression in primary prostate tumors was predictive of more aggressive tumor or disease progression. Our approach was to quantitatively determine C-MYC mRNA expression levels in micro-dissected tumor cells and matched benign epithelial cells in a radical prostatectomy cohort with long follow-up data available. On the basis of our results, we conclude that elevated C-MYC expression in primary prostate tumor may be a predictor of future biochemical recurrence. The function of C-MYC expression as potential prognostic indicator, alone or in combination with other markers, needs to be further investigated in a larger scale multicenter study.
In conclusion, this study identified elevated C-MYC expression in primary prostate tumors as a predictor of biochemical recurrence. As the deregulated C-MYC expression has been previously shown in more aggressive subtypes of CaP, its function as potential prognostic indicator necessitates further investigation. 
